BioRegenx, Inc. BRGX
OTC PK
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -23.42% | -20.75% | -24.56% | -26.79% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -23.42% | -20.75% | -24.56% | -26.79% | -- |
| Cost of Revenue | -48.89% | -48.53% | -50.02% | -52.27% | -- |
| Gross Profit | -13.94% | -9.33% | -12.03% | -13.34% | -- |
| SG&A Expenses | -56.23% | -71.10% | -42.20% | -63.15% | -- |
| Depreciation & Amortization | -102.22% | -102.22% | 0.00% | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -64.12% | -73.30% | -39.83% | -50.30% | -- |
| Operating Income | 89.73% | 92.08% | 48.21% | 59.83% | -- |
| Income Before Tax | 93.54% | 93.30% | -285.45% | -173.53% | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 93.54% | 93.30% | -285.45% | -173.53% | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 93.54% | 93.30% | -285.45% | -173.53% | -- |
| EBIT | 89.73% | 92.08% | 48.21% | 59.83% | -- |
| EBITDA | 85.75% | 90.33% | 41.04% | 73.24% | -- |
| EPS Basic | 93.97% | 93.70% | -259.02% | -126.53% | -- |
| Normalized Basic EPS | 85.71% | 88.46% | 47.37% | 63.33% | -- |
| EPS Diluted | 93.97% | 93.70% | -259.02% | -126.53% | -- |
| Normalized Diluted EPS | 85.71% | 88.46% | 47.37% | 63.33% | -- |
| Average Basic Shares Outstanding | 3.15% | 8.32% | 10.74% | 22.77% | -- |
| Average Diluted Shares Outstanding | 3.15% | 8.32% | 10.74% | 22.77% | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |